Searchable abstracts of presentations at key conferences in endocrinology

ea0083rdp3 | Reproductive and Developmental Endocrinology | EYES2022

Pharmacodynamics and safety of human recombinant luteinising hormone (LH) in hypogonadotropic hypogonadal men: a new ongoing multicenter study

F. Costantino , G. Spaggiari , L. Dalla valentina , C de Angelis , E Ferrante , C. Furini , F Garifalos , R. Indirli , F Lombardo , G. Mantovani , D Menafra , M Notarianni , F Pallotti , R Pivonello , M. Romeo , M. Simoni , D. Santi

State of the art: In pharmacology, human chorionic gonadotropin (hCG) is considered equivalent to luteinising hormone (LH) since both act on the same receptor. Thus, when testicular function needs to be clinically restored (i.e. in case of hypogonadotropic hypogonadism [HH]), hCG is used instead of LH. However, growing evidences showed LH and hCG activate different molecular pathways and offer different outcomes in women undergoing assisted reproduction. The different action b...